Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on hematologic malignancies that completed its SPAC merger with LifeSci Acquisition Corp., sponsored by LifeSci Capital, in December 2020. The blank-check vehicle had priced its IPO earlier that same year, targeting the life sciences and biotechnology sector. Vincerx has since traded as a public company developing targeted therapies for blood cancers, including candidates aimed at chronic lymphocytic leukemia. The company filed an 8-K current report with the SEC on February 6, 2025, under accession number 0001193125-25-021771. Sign up for SpacDesk to access the full filing history, deal timeline, and analytics for VINC and hundreds of other post-merger SPAC companies.